Folliculitis: Symptoms, Infection Control & Red Flags

Folliculitis is inflammation of the hair follicle, ranging from a superficial epidermal pustule (sometimes called Bockhart impetigo when staphylococcal) to a deep perifollicular abscess that destroys the follicular unit. The unifying lesion is a small papule or pustule pierced by a hair, ringed by a narrow halo of erythema, in a body region that has hair-bearing skin—so the face, beard, scalp, neck, axillae, trunk, buttocks, thighs and shins are all fair targets, while palms and soles are spared.

Although patients and clinicians often default to the word “infection”, folliculitis is a clinical pattern, not a single microbiological diagnosis. Identical-looking pustules can be driven by S. aureus (most common), Pseudomonas aeruginosa, gram-negatives released by long courses of doxycycline, the lipophilic yeast Malassezia, herpes simplex or varicella zoster virus, Demodex mites, sterile mechanical re-entry of curling hairs (pseudofolliculitis barbae), occlusive cosmetics, topical or systemic corticosteroid use, kinase inhibitors, and HIV-associated eosinophilic infiltration. Matching the right ladder of therapy to the right driver—rather than escalating antibiotics blindly—is the cardinal nursing-relevant decision.

Most folliculitis is self-limited and responds to trigger removal, gentle hygiene and short topical therapy. The minority that progresses to deep follicular abscesses (furuncles), confluent boils (carbuncles), surrounding cellulitis or systemic infection is where the ward role matters: recognising deterioration early, supporting culture and source-control decisions, and reinforcing prevention before the patient is back next month with the same eruption.

Subtype matters because it dictates therapy. The clinically useful split is by depth (superficial vs deep) and by aetiology (bacterial, fungal, viral, parasitic, drug or irritant). The grid below is the bedside cheat-sheet most ward teams find useful when triaging an eruption.

↔On a small screen, swipe or scroll sideways to see the full table.

Table adapted from current dermatology references; always defer to local prescribing pathways and antibiogram-led MRSA decisions for serious or recurrent disease.

Folliculitis usually causes minor discomfort rather than dramatic illness. Patients describe a sudden crop of small bumps that can itch, sting, or feel tender on touch. The skin around each lesion may show a rim of erythema; some pustules are pierced by a visible hair, while others sit at the follicular ostium without one.

Typical features

• Same-age cluster of follicle-centred pustules or papules, often with a central hair.
• Distribution that matches a trigger: beard for shavers, occiput/nape for those with helmets or shirt collars, swimsuit area for hot-tub exposure, upper back for sweaty athletes.
• Mild itch, prickling or stinging; tenderness when lesions sit deeper or are squeezed.
• Resolution within 7–14 days when the trigger is removed and gentle hygiene is applied.

Atypical or higher-risk features

• Single tender, fluctuant, expanding nodule—a furuncle/abscess rather than simple folliculitis.
• Confluent boggy plaque on the scalp, beard or buttock, especially with hair loss—suspect kerion, dissecting cellulitis, sycosis barbae or folliculitis decalvans.
• Rapidly spreading erythema and warmth around lesions, fever, malaise—evolving cellulitis or bacteraemia.
• Severe, intractable pruritus on face/scalp/upper trunk in a person with advanced HIV—suspect eosinophilic folliculitis.
• Painful, grouped vesicopustules that recur on the same beard zone—herpetic folliculitis, not staph.

The follicle is a microenvironment of warm sebum, keratin and skin commensals; almost any insult that breaches the surface barrier or shifts the local flora can ignite folliculitis. Many cases are multifactorial—shaving plus occlusive clothing plus diabetes, for example—so the clinical history is more useful than a single swab.

Pathogen-driven mechanisms

• Bacterial: S. aureus (including MRSA) is the most common; Pseudomonas aeruginosa from inadequately disinfected hot tubs, whirlpools and pools causes the classic “hot-tub rash”; gram-negatives such as Klebsiella, Proteus and Enterobacter emerge in patients on long oral antibiotics for acne.
• Fungal: Malassezia furfur exploits oily skin, antibiotic-shifted flora and immunosuppression; dermatophytes (tinea capitis, Majocchi granuloma) invade follicles in scalp and trunk tinea, especially in diabetes or topical-steroid-modified eruptions.
• Viral: herpes simplex causes recurrent grouped vesicopustules in the beard area; varicella zoster and molluscum contagiosum can mimic folliculitis.
• Parasitic: Demodex folliculorum drives a rosacea-like facial folliculitis in older or immunosuppressed patients; scabies often produces a mixed pustular and papular eruption mistaken for folliculitis.

Mechanical, chemical and host risk factors

• Frequent shaving, waxing, plucking or epilation (especially against the grain or with curled hair anatomy).
• Hot, humid or occlusive environments—wet suits, sports padding, tight athletic wear, helmets, sustained pressure under back braces.
• Hot-tub, whirlpool, pool or spa exposure with poor disinfection and pH outside the 7.0–7.8 range.
• Prolonged topical or oral corticosteroids (steroid acne pattern) and topical occlusive emollients (paraffin, oils, coal tar).
• Long oral antibiotic courses for acne, allowing gram-negative or yeast overgrowth.
• EGFR inhibitors, BRAF/MEK inhibitors, lithium, isoniazid, phenytoin, B-complex and cyclosporine.
• Type 2 diabetes, obesity, immunosuppression including HIV/AIDS with low CD4, post-transplant therapy and chemotherapy.
• Persistent S. aureus nasal or perineal carriage and household contacts with recurrent staphylococcal carriage and infection.

Folliculitis is fundamentally a clinical diagnosis—a focused history and a careful look at lesion morphology, distribution and timing close to a trigger usually settles it. Investigations are layered on top only when subtype, recurrence or severity changes management.

Clinical assessment

• Map the eruption to the body region (beard, scalp, trunk, swimsuit area, lower legs) and ask about shaving practices, hair-removal devices, recent water exposures, sports gear and occupational chemicals.
• Take a medication and supplement history—long oral antibiotic courses, topical and inhaled corticosteroids, lithium, anticonvulsants, EGFR/BRAF/MEK inhibitors, B-complex—plus past dermatology diagnoses.
• Document depth: superficial pustules vs tender perifollicular nodules; bilateral and symmetrical patterns vs single hot spot; presence of a fluctuant lesion needing drainage.
• Use a structured skin assessment on every visit so handovers carry objective findings rather than “rash same as before”.

Bedside & laboratory investigations

• Pus swab for Gram stain & culture (skin culture or wound culture): reserved for recurrent, treatment-failed, deep or severe disease, immunocompromised hosts and outbreak settings; route through standard aseptic specimen collection protocols.
• KOH or PAS-stained skin scraping / pluck: when monomorphic upper-trunk pustules suggest Malassezia or scaling/alopecia hints at tinea capitis or Majocchi granuloma.
• HSV PCR / Tzanck smear: for grouped recurrent vesicopustular beard or facial eruptions.
• Punch skin biopsy: when eosinophilic folliculitis, folliculitis decalvans, lichen planopilaris or other scarring/inflammatory mimics are on the table.
• Blood cultures: only if systemic features evolve toward bacteraemia or sepsis.

Pattern-based diagnostic flow

↔On a small screen, swipe or scroll sideways to see the full table.

Several conditions imitate folliculitis or coexist with it. Anchoring on a single label can either delay treatment of a more serious mimic or fuel unnecessary antibiotic cycles. The high-yield comparators below cover most everyday confusion.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy follows the subtype. Most superficial folliculitis responds to gentle measures; deeper, recurrent or specialised forms need a targeted prescription. The ladders below are aligned with major dermatology references and antimicrobial stewardship principles—always cross-check local antibiograms and allergy histories before initiating.

First-line: superficial bacterial folliculitis

• Trigger removal: pause shaving for 7–10 days; switch to single-blade or electric razor; loosen occlusive clothing and pads; wash exercise gear after each use.
• Antiseptic skin care: chlorhexidine or benzoyl peroxide 5% wash daily for 5–7 days while showering.
• Topical mupirocin 2% or topical clindamycin twice daily for 7–10 days to limited areas.
• Warm compresses 10–15 minutes, several times a day, to support drainage and comfort—coupled with strict hand hygiene to limit autoinoculation.

Second-line: extensive, deep or recurrent staphylococcal disease

• Oral cephalexin 250–500 mg three to four times daily for 7–10 days for MSSA-driven extensive disease (per Merck Manual / dermatology references); oral dicloxacillin is an alternative where available.
• Add anti-MRSA cover (e.g. trimethoprim-sulfamethoxazole or doxycycline) when local epidemiology, prior MRSA infection, abscess or hospital exposure suggests resistance, in line with IDSA skin and soft-tissue infection guidance.
• Decolonisation pathway (intranasal mupirocin plus chlorhexidine body wash) for recurrent disease, household clusters, or documented carriage.
• Consider incision and drainage of furuncles >5 mm under sterile wound care standards; dressings and packing managed with appropriate wound irrigation and serial review.

Pseudomonas (hot-tub) folliculitis

• Stop the implicated venue exposure; most patients resolve over 7–14 days without systemic therapy.
• Topical acetic-acid soaks or symptomatic antipruritics; oral ciprofloxacin only for severe, prolonged or immunocompromised cases.
• Encourage notification of the venue and, where multiple bathers are affected, public-health reporting per local outbreak rules.

Gram-negative folliculitis emerging on long acne antibiotics

• Stop the offending tetracycline; coordinate with dermatology for definitive treatment.
• Options include isotretinoin (with the appropriate pregnancy-prevention programme), ampicillin or trimethoprim-sulfamethoxazole.

Malassezia (Pityrosporum) folliculitis

• Oral itraconazole 200 mg daily for 1–3 weeks or fluconazole 100–200 mg weekly for 2–4 weeks; topical ketoconazole 2% shampoo as a body wash 3–4 times weekly.
• Avoid greasy moisturisers, oils and antibiotics that suppress competing flora; expect relapse and plan a maintenance topical regimen.

Tinea-related folliculitis (Majocchi granuloma, kerion)

• Oral antifungal—usually terbinafine or itraconazole—per duration recommended for the underlying tinea; topical agents alone are inadequate when follicles are involved.
• Discontinue any potent topical steroid that has been masking the eruption (tinea incognito) before starting antifungals.

Herpetic, parasitic and eosinophilic forms

• Herpetic folliculitis: standard oral acyclovir, valacyclovir or famciclovir per facial herpes pathways; episodic vs suppressive plans set by prescriber.
• Demodex folliculitis: topical permethrin 5% as initial choice; oral ivermectin and/or metronidazole when topical fails or disease is widespread, per dermatology guidance.
• HIV-associated eosinophilic folliculitis: antiretroviral therapy is the backbone, supported by topical corticosteroids, antihistamines, phototherapy or itraconazole; flares within the first six months of ART are well documented.

Pseudofolliculitis barbae (irritant)

• Stop close shaving for at least 3–4 weeks; once re-introduced, use single-blade razors with the grain or electric clippers leaving 1–2 mm stubble.
• Topical retinoids (tretinoin/adapalene) and short courses of low-potency topical steroids for inflammation; tackle pruritus with bland emollients.
• Long-term laser hair reduction is the most effective definitive option in tightly curled hair phenotypes.
• Antibiotics only when secondary infection (folliculitis barbae) is documented—not as routine practice.

Special populations

• Pregnancy: prefer topical mupirocin or short oral cephalosporins where systemic therapy is needed; coordinate with the obstetric formulary before substituting.
• Children: hot-tub folliculitis in healthy children rarely needs antibiotics; impetiginised forms managed with topical mupirocin and hygiene measures.
• Diabetes, transplant, neutropenia: lower threshold for culture, anti-MRSA cover and earlier escalation when nodules, fever or rapid spread emerge.

Folliculitis is a reliable platform for stewardship, patient education and small-but-meaningful nursing interventions. Operationalising care around clear monitoring intervals, drug-checks and escalation triggers prevents the common drift toward repeated antibiotic courses without diagnostic re-think.

• Review interval: reassess at 7–10 days for superficial bacterial folliculitis; if no improvement, reconsider the diagnosis (Malassezia? herpes? irritant?) before extending or rotating antibiotics.
• Treatment failure rules: persistence beyond two weeks of appropriate therapy, recurrence within four weeks, or worsening monomorphic upper-trunk distribution are pre-defined cues to swab, scrape or refer to dermatology.
• MRSA risk flag: record nasal carriage, household crowding, prior boils or abscesses, contact sport, hospitalisation or injecting drug use; influence empirical choice and isolation per local isolation precautions.
• Drainage support: for fluctuant lesions, support sterile incision and drainage; route post-procedure care via standard wound bundles, including dressings and wound measurement—and use drain management standards if a drain is placed.
• Stewardship: avoid topical-then-oral-then-different-oral antibiotic cycling without a microbiology-driven rationale; document why each escalation step is needed.
• Public-health link: for clusters in gyms, sports teams, residential settings or hot-tub venues, notify infection control and, when appropriate, public health—especially for suspected MRSA outbreaks or Pseudomonas-related pool incidents.

Bedside monitoring checklist

• Number and depth of lesions; presence of any new fluctuant nodule.
• Borders of erythema—mark with pen and date, particularly when cellulitis is suspected.
• Vital signs trend (fever, tachycardia) in any patient with deeper or extensive disease.
• Pain trajectory, sleep impact and itch severity; flag worsening pruritus in HIV.
• Adherence to topical agents, occlusion behaviours and shaving modifications.

• Furunculosis and carbunculosis—deeper, fluctuant collections that often need drainage and oral antibiotics.
• Surrounding cellulitis or, rarely, bacteraemia and sepsis in immunocompromised hosts and people with diabetes.
• Permanent hair loss and scarring from deep, recurrent or sterile inflammatory forms (folliculitis decalvans, dissecting cellulitis of the scalp, kerion); consult hair loss pathways for diagnosis.
• Post-inflammatory hyperpigmentation and keloid scarring, especially in skin of colour after pseudofolliculitis barbae or untreated deep folliculitis on neck/jaw.
• Recurrent staphylococcal infection clusters in households, sports teams or correctional settings.
• Drug reactions and Clostridioides difficile infection from unnecessary or extended antibiotic courses.

Folliculitis prevention is mostly about modifying the trigger, not stocking up on antibiotics. Patient education, when it sticks, prevents most recurrences.

• Shaving hygiene: clean razor each use, shave with the grain, avoid daily close shaves on prone areas, swap to electric razors or longer stubble for tightly curled hair.
• Sweat and occlusion management: shower and change out of damp athletic wear promptly; avoid oily, occlusive moisturisers and coal tar on hair-bearing skin.
• Hot-tub and pool safety: use venues with documented disinfection (free chlorine ≥3 ppm or bromine 4–8 ppm and pH 7.0–7.8 in hot tubs per CDC), shower after use, wash and dry swimsuits between uses.
• Antibiotic stewardship: reassess long acne antibiotic courses at 6–12 weeks rather than indefinite refills; combine with benzoyl peroxide to limit resistance.
• Decolonisation programmes when MRSA or recurrent staphylococcal folliculitis is documented in the household.
• Tight glycaemic and immunosuppression management in higher-risk hosts; review of corticosteroid and EGFR/BRAF inhibitor regimens with prescribers when persistent eruptions appear.

Most folliculitis is benign and self-limited, especially when the trigger is identified and removed early. Superficial bacterial and Pseudomonas (hot-tub) cases typically clear within one to two weeks; Malassezia folliculitis often clears within a month of correct antifungal therapy but recurs without ongoing topical maintenance. Deep, recurrent or sterile inflammatory forms (folliculitis decalvans, dissecting cellulitis, kerion) carry the highest scarring and alopecia risk, and outcomes hinge on timely dermatology input.

Mortality is rare and concentrates in immunocompromised hosts who develop bacteraemia or in delayed recognition of cellulitis or necrotising infection masquerading as folliculitis. Pseudofolliculitis barbae is a chronic but cosmetic-grade condition with good control through technique and laser; psychosocial impact, particularly facial scarring in skin of colour, deserves explicit acknowledgment in counselling.

Triage and assessment

Three minutes of structured questions—shaving habits, water exposures, current medications, and a tour of the lesion distribution—usually narrows the subtype before any swab is taken. Photograph (with consent) the worst and most representative areas to give the next clinician something better than “rash unchanged”.

Education and adherence

Patients want to scratch, squeeze and shave through it. Explicit instructions to avoid all three—and to use one antiseptic wash plus one topical for the agreed window—prevent relapse. For hot-tub folliculitis, walk the patient through what well-maintained chlorination looks like rather than telling them to “avoid hot tubs forever”.

Documentation & escalation

• Record lesion type, depth, distribution, suspected subtype and chosen therapy with rationale.
• Trigger early review when systemic symptoms, fluctuant nodules or rapid expansion appear.
• Flag patients on long oral antibiotics or topical steroids for review with the prescriber when monomorphic facial pustules emerge.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of folliculitis subtype recognition (S. aureus / hot-tub Pseudomonas / fungal Malassezia / pseudo-folliculitis), structured topical / oral antimicrobial therapy and the deep-furuncle / abscess / cellulitis / sepsis red flags.